Daiwa: Maintains target price of HK$67 for Sino Biopharmaceutical (01801.HK) and rates it as "buy"

According to the Chinese financial news app, Morgan Stanley has released a research report stating that the commercial market dynamics information for Sinobioway Biomedicine (01801.HK) in the next few quarters is expected to indicate the supply and demand dynamics of the new domestic GLP1 blood sugar lowering treatment drug. The target price of 67 Hong Kong dollars and the "Buy" rating are maintained for now.